Day One Biopharmaceuticals, Inc.DAWNEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
Day One Biopharmaceuticals is a clinical-stage biopharmaceutical firm focused on developing targeted precision oncology therapies for pediatric and young adult patients with genetically driven cancers. It advances novel drug candidates to address unmet medical needs in underserved patient segments, operating primarily in the U.S. and partnering with global oncology research institutions.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| FMR LLC | 11.19% | 11.3M | ▲ +3.65pp | 2024-11-07 |
| NOS. OF ABOVE PERSONS | 9.00% | 7.8M | — | 2024-02-14 |
| BlackRock, Inc. | 5.90% | 5.1M | — | 2024-01-29 |
| Atlas Venture Fund XI, L.P. | 5.50% | 4.8M | ▼ -1.40pp | 2024-11-14 |
| The Vanguard Group | 5.48% | 4.8M | — | 2024-02-13 |
Insider Transactions
Net 90d: −$277.98M · buys $0 / sells $277.98MRange:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-04-23 | AI Day1 LLC | 10% Owner | Disposed (U) | 12.93M | $21.50 | $277.98M |
| 2026-04-23 | Saira Ramasastry | Director | Disposition | 40.5K | — | — |
| 2026-04-23 | Holles Natalie C. | Director | Disposition | 57.3K | — | — |
| 2026-04-23 | York Charles N II | COO and CFO | Disposition | 312.0K | — | — |
| 2026-04-23 | VASCONCELLES MICHAEL | Head of Research and Dev. | Disposition | 4.4K | — | — |
| 2026-04-23 | Adam Dubow | Gen Counsel & Secretary | Disposition | 72.7K | — | — |
| 2026-04-23 | Josey John A. | Director | Disposition | 72.3K | — | — |
| 2026-04-23 | Lauren Merendino | Chief Commercial Officer | Disposition | 60.2K | — | — |
| 2026-04-23 | Jeremy Bender | CHIEF EXECUTIVE OFFICER | Disposition | 204.6K | — | — |
| 2026-04-23 | Jeremy Bender | CHIEF EXECUTIVE OFFICER | Disposition | 20.2K | — | — |
1–10 of 15
Page 1 / 2